Clinical Efficacy of Feiyiliu Mixture Combined with AP Chemotherapy Regimen in Treatment of Non-small Cell Lung Cancer

LIU Si-yuan; LI Zhi-peng; ZHENG Xin

doi:10.13422/j.cnki.syfjx.2018030185

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Feiyiliu Mixture Combined with AP Chemotherapy Regimen in Treatment of Non-small Cell Lung Cancer

更新时间：2024-01-04

- Clinical Efficacy of Feiyiliu Mixture Combined with AP Chemotherapy Regimen in Treatment of Non-small Cell Lung Cancer
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 24, Issue 3, Pages: 185-190(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2018030185
  CLC： R734.2
- Published：2018
- 稿件说明：
移动端阅览
LIU Si-yuan, LI Zhi-peng, ZHENG Xin. Clinical Efficacy of Feiyiliu Mixture Combined with AP Chemotherapy Regimen in Treatment of Non-small Cell Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(3): 185-190.
DOI：

LIU Si-yuan, LI Zhi-peng, ZHENG Xin. Clinical Efficacy of Feiyiliu Mixture Combined with AP Chemotherapy Regimen in Treatment of Non-small Cell Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(3): 185-190. DOI： 10.13422/j.cnki.syfjx.2018030185.

摘要

目的：观察肺抑瘤合剂联合AP （培美曲塞+顺铂）化疗方案治疗非小细胞肺癌临床疗效及对细胞炎性因子的影响。方法：选择符合纳入标准的非小细胞肺癌患者62例，采用简单数字的随机方法分为对照组和治疗组，每组31例。两组均采用规范的西药治疗，对照组给予AP （培美曲塞+顺铂）化疗方案，在此基础上给予复方斑蝥胶囊口服，3粒/次，2次/d。治疗组在AP （培美曲塞+顺铂）方案基础上给予肺抑瘤合剂口服，每次100 mL，3次/d。观察两组患者治疗前后生活质量评分、临床证候积分、血清中细胞炎性因子白细胞介素（IL）-6，IL-17，前列腺素E2（PGE2）水平变化，以及治疗后两组间瘤体改善情况、不良事件发生率，统计临床疗效。结果：治疗组治疗后在生活质量评分、证候积分（咳嗽、咳血、胸痛、乏力、发热）、血清中细胞炎性因子（IL-6，IL-17，PGE2）水平较治疗前明显改善，且优于对照组（P<0.05）；治疗组治疗后瘤体的稳定率明显优于对照组（P<0.05），且不良事件发生率低于对照组（P<0.05）。结论：肺抑瘤合剂联合AP化疗方案能更有效地改善非小细胞肺癌患者生活质量、临床症状及实体瘤大小，降低细胞炎性因子在患者血清中的表达，降低临床不良事件的发生，值得进一步推广研究。

Abstract

Objective:To observe the clinical efficacy of Feiyiliu mixture and AP chemotherapy (pemetrexed + cis-platinum) in the treatment of non-small cell lung cancer and its effect on inflammatory factors. Method:The 62 patients with non-small cell lung cancer who met the inclusion criteria were randomly divided into the control group and the treatment group

with 31 patients in each group. The control group was given AP chemotherapy regimen and compound cantharis capsule

3 pills/time

bid; the treatment group was orally given Feiyiliu mixture in addition of AP regimen

100 mL/time

tid. The changes in scores of quality of life

symptom scores

interleukin (IL)-6

IL-17

prostaglandin E2 (PGE2) solid tumor after treatment

and incidence of adverse events were observed in two groups before and after treatment

and the clinical efficacy was evaluated. Result:The treatment group's scores of quality of life

integral syndrome (cough

hemoptysis

chest pain

fatigue and fever) and cytokines (IL-6

IL-17

PGE2) after treatment were significantly lower than those of control group (P<0.05); the rate of tumor stability after treatment was significantly better than that of control group (P<0.05); the incidence of adverse events was lower than that of control group (P < 0.05). Conclusion:Feiyiliu mixture combined with AP chemotherapy can effectively improve quality of life

clinical symptoms and tumor size in patients with non-small cell lung cancer

and decrease the expressions of inflammatory cytokines in serum of the patients

and is worth further promotion.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Feiyiliu Mixture on Prognosis of Patients with Middle and Advanced Squamous Cell Carcinoma of Lung

Buzhong Yiqitang Regulates Endoplasmic Reticulum Stress to Attenuate Cisplatin Resistance in Non-small Cell Lung Cancer via Nrf2/ROS Pathway

Buzhong Yiqitang Regulates Endoplasmic Reticulum Stress via Nrf2/ROS/PERK/CHOP Signaling Pathway to Attenuate Cisplatin Resistance in NSCLC

Buzhong Yiqitang Regulates Apoptosis via Nrf2/ROS Pathway to Alleviate Cisplatin Resistance in A549/DDP Cells

Mechanism of PI3K/Akt/mTOR Signaling Pathway Against Non-small Cell Lung Cancer and Chinese Medicine Intervention： A Review

Related Author

Xian-tao LIU

Xin ZHENG

YU Dan

MU Qirui

LI He

LIU Yuetong

HUANG Jingyi

GAO Yuan

Related Institution

Affiliated Hospital of Shandong University of Traditional Chinese Medicine(TCM)

Shandong University of TCM

College of Integrated Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine

College of Integrated Traditional Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine

College of Integrative Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰